Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Tabs

Article

konjac mannan, glucomannan, glycaemic control, weight management, body weight, blood lipids, blood glucose, bowel function, intestinal transit, potentially pathogenic organisms, health claims

First published in the EFSA Journal:

19 October 2010

Adopted:

10 September 2010

Last Updated:

9 December 2010. This version replaces the previous one/s.

Type:

Opinion of the Scientific Committee/Scientific Panel

Read it on the Wiley Online Library: Article | PDF

Abstract:

No abstract available

Panel members at the time of adoption:

Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.

Panel on Dietetic Products, Nutrition and Allergies

Contact:

nda [at] efsa.europa.eu

doi:

10.2903/j.efsa.2010.1798

EFSA Journal 2010;8(10):1798 [27 pp.].

Question Number: